Medicare billing address
CMS Medicare provider billing file
1107 Rush AveBellefontaine, OH 43311
CMS public data · NPI 1134330079
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Muhammad I Azrak, MD
Specialty
Credential
MD
NPI
1134330079
Primary source state
OH
Data retrieval date
July 28, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Muhammad I Azrak, MD from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
1107 Rush AveCMS Doctors & Clinicians file
1107 Rush AveCMS Doctors & Clinicians file
730 W Market StIn the 2024 CMS provider billing file, this NPI had 940 Medicare beneficiaries and 5,601 total services. The average beneficiary age was 76, and the average HCC risk score was 1.1.
Total Medicare allowed amount
$546,495.37
Total Medicare payment amount
$395,458.18
Medicare beneficiaries
940
Total services
5,601
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hypertension
75%
CMS beneficiary-panel share
Hyperlipidemia
73%
CMS beneficiary-panel share
Diabetes
33%
CMS beneficiary-panel share
Ischemic heart disease
28%
CMS beneficiary-panel share
Chronic kidney disease
23%
CMS beneficiary-panel share
Atrial fibrillation
20%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Imaging of retina | 1,030 | $36.70 |
| Exam of the internal drainage system of eye | 733 | $25.37 |
| Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 541 | $120.58 |
| Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 447 | $85.31 |
| Imaging of optic nerve | 424 | $33.20 |
| Exam of visual field with extended testing | 351 | $57.53 |
| Established patient complete exam of visual system | 271 | $116.65 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 244 | $15.67 |
| Injection of drug into eye | 202 | $105.03 |
| Measurement of corneal curvature and depth of eye | 146 | $37.26 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1134330079. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Latanoprost | Latanoprost | 719 | 1,733.9 | $6,943.39 |
| 2 | Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 432 | 1,105 | $8,292.76 |
| 3 | Timolol Maleate | Timolol Maleate | 298 | 724.8 | $3,228.78 |
| 4 | Brimonidine Tartrate | Brimonidine Tartrate | 177 | 409.9 | $2,008.79 |
| 5 | Prednisolone Acetate | Prednisolone Acetate | 129 | 186.5 | $4,048.24 |
| 6 | Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 75 | 80.4 | $728.10 |
| 7 | Erythromycin | Erythromycin Base | 74 | 74 | $764.80 |
| 8 | Acetazolamide Er | Acetazolamide | 61 | 79 | $1,849.79 |
| 9 | Dorzolamide Hcl | Dorzolamide Hcl | 48 | 104.2 | $565.23 |
| 10 | Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 43 | 78.3 | $6,148.63 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Graduation year
2000
Group/practice field
J. Terebuh Md Inc
Telehealth reported
Not reported
Secondary specialty fields reported by CMS: Ophthalmology.
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.